Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other Events
Item 8.01 Other Events.

On June5, 2018, Synergy Pharmaceuticals Inc. (the “Company”) issued a press release announcing new data presented at Digestive Disease Week (DDW) 2018 showing chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are associated with depressed levels of uroguanylin, a naturally occurring and endogenous human GI peptide. In addition, the Company presented a new risk/benefit analysis from pooled Phase 3 study data evaluating TRULANCE®(plecanatide) and linaclotide for the treatment of adults with chronic idiopathic constipation (CIC). These findings were presented as a poster at DDW 2018 in Washington D.C. The press releases are attached as Exhibit99.1 and 99.2 to this report on Form8-K and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

SYNERGY PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a18-14478_2ex99d1.htm EX-99.1 Exhibit 99.1   NEWS RELEASE   Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C)   NEW YORK — June 5,…
To view the full exhibit click here

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.